General Information of Drug (ID: DMD4381)

Drug Name
Terbutaline
Synonyms
Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1]
Bronchitis CA20 Approved [2]
Pulmonary emphysema CA21.Z Approved [2]
Severe asthma CA23 Approved [2]
Pruritus EC90 Investigative [2]
Therapeutic Class
Bronchodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 225.28
Logarithm of the Partition Coefficient (xlogp) 0.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.7 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
The bioavailability of drug is 85% [3]
Clearance
The clearance of drug is 3.0 mL/min/kg [5]
Elimination
An oral dose of terbutaline is 40% eliminated in the urine after 72 hours [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.4 hours [7]
Metabolism
The drug is metabolized via sulphated or glucuronidated [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.10968 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.75% [10]
Vd
The volume of distribution (Vd) of drug is 1.6 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 213 mg/mL [4]
Chemical Identifiers
Formula
C12H19NO3
IUPAC Name
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
Canonical SMILES
CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
InChI
InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
InChIKey
XWTYSIMOBUGWOL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5403
ChEBI ID
CHEBI:9449
CAS Number
23031-25-6
DrugBank ID
DB00871
TTD ID
D0M8RC
VARIDT ID
DR00971
ACDINA ID
D00664
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-1B adrenergic receptor (ADRA1B) OTSAYAFD ADA1B_HUMAN Gene/Protein Processing [13]
Alpha-1D adrenergic receptor (ADRA1D) OTW2CD1O ADA1D_HUMAN Gene/Protein Processing [13]
Alpha-2-HS-glycoprotein (AHSG) OTUG0LEA FETUA_HUMAN Drug Response [14]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Drug Response [15]
Corticoliberin (CRH) OT2MOC4T CRF_HUMAN Gene/Protein Processing [16]
Gastrin (GAST) OTD0IP9N GAST_HUMAN Protein Interaction/Cellular Processes [17]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Gene/Protein Processing [18]
Insulin (INS) OTZ85PDU INS_HUMAN Gene/Protein Processing [19]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Gene/Protein Processing [20]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Gene/Protein Processing [21]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Asthma
ICD Disease Classification CA23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 4.88E-01 -0.05 -0.12
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 7.10E-01 0.06 0.09
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.48E-01 6.33E-02 3.20E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.74E-02 1.21E-01 4.40E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Terbutaline
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Budesonide DMJIBAW Minor Increased risk of hypokalemia by the combination of Terbutaline and Budesonide. Asthma [CA23] [22]
Coadministration of a Drug Treating the Disease Different from Terbutaline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Terbutaline and Methylene blue. Acquired methaemoglobinaemia [3A93] [23]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Terbutaline and Ivosidenib. Acute myeloid leukaemia [2A60] [24]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Midostaurin. Acute myeloid leukaemia [2A60] [24]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Idarubicin. Acute myeloid leukaemia [2A60] [24]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Arn-509. Acute myeloid leukaemia [2A60] [24]
Gilteritinib DMTI0ZO Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Gilteritinib. Acute myeloid leukaemia [2A60] [24]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Oliceridine. Acute pain [MG31] [24]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rivastigmine. Alzheimer disease [8A20] [25]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Terbutaline and Metronidazole. Amoebiasis [1A36] [26]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ivabradine. Angina pectoris [BA40] [24]
Bepridil DM0RKS4 Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bepridil. Angina pectoris [BA40] [24]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Terbutaline and Dronedarone. Angina pectoris [BA40] [24]
Bedaquiline DM3906J Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [24]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Cilostazol. Arterial occlusive disease [BD40] [24]
Posaconazole DMUL5EW Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Posaconazole. Aspergillosis [1F20] [24]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [24]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Terbutaline and Droxidopa. Autonomic nervous system disorder [8D87] [27]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Ofloxacin. Bacterial infection [1A00-1C4Z] [24]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Clarithromycin. Bacterial infection [1A00-1C4Z] [24]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Terbutaline and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [25]
Sparfloxacin DMB4HCT Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sparfloxacin. Bacterial infection [1A00-1C4Z] [24]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Gemifloxacin. Bacterial infection [1A00-1C4Z] [24]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Norfloxacin. Bacterial infection [1A00-1C4Z] [24]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Levofloxacin. Bacterial infection [1A00-1C4Z] [24]
Lomefloxacin DMVRH9C Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lomefloxacin. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Telithromycin. Bacterial infection [1A00-1C4Z] [24]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Retigabine. Behcet disease [4A62] [24]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Eribulin. Breast cancer [2C60-2C6Y] [24]
Lapatinib DM3BH1Y Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lapatinib. Breast cancer [2C60-2C6Y] [24]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bosutinib. Breast cancer [2C60-2C6Y] [24]
Corticotropin DMP9TWZ Minor Increased risk of hypokalemia by the combination of Terbutaline and Corticotropin. Chronic kidney disease [GB61] [22]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [24]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Terbutaline and Levomilnacipran. Chronic pain [MG30] [28]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Terbutaline and Atracurium. Corneal disease [9A76-9A78] [29]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Terbutaline and Mivacurium. Corneal disease [9A76-9A78] [29]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Halothane. Corneal disease [9A76-9A78] [24]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Terbutaline and Pancuronium. Corneal disease [9A76-9A78] [29]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sevoflurane. Corneal disease [9A76-9A78] [24]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Probucol. Coronary atherosclerosis [BA80] [24]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Terbutaline and Pasireotide. Cushing syndrome [5A70] [24]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Osilodrostat. Cushing syndrome [5A70] [24]
Sertraline DM0FB1J Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sertraline. Depression [6A70-6A7Z] [24]
Selegiline DM6034S Moderate Additive hypertensive effects by the combination of Terbutaline and Selegiline. Depression [6A70-6A7Z] [23]
Isocarboxazid DMAF1NB Moderate Additive hypertensive effects by the combination of Terbutaline and Isocarboxazid. Depression [6A70-6A7Z] [23]
Milnacipran DMBFE74 Moderate Increased risk of rapid heart rate by the combination of Terbutaline and Milnacipran. Depression [6A70-6A7Z] [28]
Escitalopram DMFK9HG Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Escitalopram. Depression [6A70-6A7Z] [24]
Desvenlafaxine DMHD4PE Moderate Additive hypertensive effects by the combination of Terbutaline and Desvenlafaxine. Depression [6A70-6A7Z] [28]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Maprotiline. Depression [6A70-6A7Z] [24]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [24]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Deutetrabenazine. Dystonic disorder [8A02] [24]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Ingrezza. Dystonic disorder [8A02] [24]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Solifenacin. Functional bladder disorder [GC50] [24]
Ketoconazole DMPZI3Q Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ketoconazole. Fungal infection [1F29-1F2F] [24]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sunitinib. Gastrointestinal stromal tumour [2B5B] [24]
Procarbazine DMIK367 Moderate Additive hypertensive effects by the combination of Terbutaline and Procarbazine. Hodgkin lymphoma [2B30] [23]
Fostemsavir DM50ILT Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Terbutaline and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [24]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Polyethylene glycol. Irritable bowel syndrome [DD91] [31]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Phenolphthalein. Irritable bowel syndrome [DD91] [25]
Crizotinib DM4F29C Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Crizotinib. Lung cancer [2C25] [24]
Ceritinib DMB920Z Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ceritinib. Lung cancer [2C25] [24]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Terbutaline and Osimertinib. Lung cancer [2C25] [24]
Selpercatinib DMZR15V Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Selpercatinib. Lung cancer [2C25] [24]
Lumefantrine DM29GAD Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lumefantrine. Malaria [1F40-1F45] [24]
Halofantrine DMOMK1V Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Halofantrine. Malaria [1F40-1F45] [24]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Hydroxychloroquine. Malaria [1F40-1F45] [24]
Primaquine DMWQ16I Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Primaquine. Malaria [1F40-1F45] [24]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [24]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Terbutaline and Arsenic trioxide. Mature B-cell lymphoma [2A85] [24]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Terbutaline and Vemurafenib. Melanoma [2C30] [24]
LGX818 DMNQXV8 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and LGX818. Melanoma [2C30] [24]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Terbutaline and Panobinostat. Multiple myeloma [2A83] [24]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Thalidomide. Multiple myeloma [2A83] [26]
Siponimod DM2R86O Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Siponimod. Multiple sclerosis [8A40] [24]
Fingolimod DM5JVAN Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Fingolimod. Multiple sclerosis [8A40] [24]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ozanimod. Multiple sclerosis [8A40] [32]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Romidepsin. Mycosis fungoides [2B01] [24]
Nilotinib DM7HXWT Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Nilotinib. Myeloproliferative neoplasm [2A20] [24]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Dasatinib. Myeloproliferative neoplasm [2A20] [24]
Promethazine DM6I5GR Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Promethazine. Nausea/vomiting [MD90] [24]
Granisetron DMIUW25 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Granisetron. Nausea/vomiting [MD90] [24]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Ondansetron. Nausea/vomiting [MD90] [24]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Entrectinib. Non-small cell lung cancer [2C25] [24]
Sibutramine DMFJTDI Moderate Additive hypertensive effects by the combination of Terbutaline and Sibutramine. Obesity [5B80-5B81] [33]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Levomethadyl Acetate. Opioid use disorder [6C43] [24]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Lofexidine. Opioid use disorder [6C43] [24]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rucaparib. Ovarian cancer [2C73] [24]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Buprenorphine. Pain [MG30-MG3Z] [24]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Triclabendazole. Parasitic worm infestation [1F90] [24]
Safinamide DM0YWJC Moderate Additive hypertensive effects by the combination of Terbutaline and Safinamide. Parkinsonism [8A00] [23]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Terbutaline and Rasagiline. Parkinsonism [8A00] [23]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Pimavanserin. Parkinsonism [8A00] [24]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Famotidine. Peptic ulcer [DA61] [26]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Terbutaline and Macimorelin. Pituitary gland disorder [5A60-5A61] [34]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Terbutaline and Lefamulin. Pneumonia [CA40] [24]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Degarelix. Prostate cancer [2C82] [24]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Terbutaline and ABIRATERONE. Prostate cancer [2C82] [24]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Enzalutamide. Prostate cancer [2C82] [24]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Relugolix. Prostate cancer [2C82] [24]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Bicalutamide. Prostate cancer [2C82] [24]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Terbutaline and Gatifloxacin. Respiratory infection [CA07-CA4Z] [24]
Ciclesonide DM2NA4K Minor Increased risk of hypokalemia by the combination of Terbutaline and Ciclesonide. Respiratory system disease [CB40-CB7Z] [22]
Dexamethasone DMMWZET Minor Increased risk of hypokalemia by the combination of Terbutaline and Dexamethasone. Rheumatoid arthritis [FA20] [22]
Quetiapine DM1N62C Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Quetiapine. Schizophrenia [6A20] [24]
Mesoridazine DM2ZGAN Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Mesoridazine. Schizophrenia [6A20] [24]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Aripiprazole. Schizophrenia [6A20] [26]
Iloperidone DM6AUFY Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Iloperidone. Schizophrenia [6A20] [24]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Paliperidone. Schizophrenia [6A20] [24]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Terbutaline and Amisulpride. Schizophrenia [6A20] [24]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Asenapine. Schizophrenia [6A20] [24]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Pimozide. Schizophrenia [6A20] [24]
Methylprednisolone DM4BDON Minor Increased risk of hypokalemia by the combination of Terbutaline and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [22]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Terbutaline and LEE011. Solid tumour/cancer [2A00-2F9Z] [25]
Vandetanib DMRICNP Major Increased risk of ventricular arrhythmias by the combination of Terbutaline and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [24]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [24]
Doxorubicin DMVP5YE Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [24]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Pitolisant. Somnolence [MG42] [24]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [24]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Terbutaline and Lenvatinib. Thyroid cancer [2D10] [24]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Terbutaline and Cabozantinib. Thyroid cancer [2D10] [24]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Terbutaline and Papaverine. Tonus and reflex abnormality [MB47] [35]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Terbutaline and Vecuronium. Tonus and reflex abnormality [MB47] [29]
Trimeprazine DMEMV9D Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [30]
Fluticasone DMGCSVF Minor Increased risk of hypokalemia by the combination of Terbutaline and Fluticasone. Vasomotor/allergic rhinitis [CA08] [22]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Terbutaline and Procainamide. Ventricular tachyarrhythmia [BC71] [24]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Propafenone. Ventricular tachyarrhythmia [BC71] [24]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Terbutaline and Flecainide. Ventricular tachyarrhythmia [BC71] [24]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Terbutaline and Amiodarone. Ventricular tachyarrhythmia [BC71] [24]
⏷ Show the Full List of 130 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Edetate disodium E00186 8759 Complexing agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Terbutaline Sulfate 2.5mg tablet 2.5mg Tablet Oral
Terbutaline Sulfate 5mg tablet 5mg Tablet Oral
Terbutaline Sulfate 1mg/ml injectable 1mg/ml Injectable Injection
Terbutaline 2.5 mg tablet 2.5 mg Oral Tablet Oral
Terbutaline 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 560).
2 Terbutaline FDA Label
3 Summary of Product Characteristics: Galvus (vildagliptin) oral tablets
4 BDDCS applied to over 900 drugs
5 Nyberg L: Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis Suppl. 1984;134:149-60.
6 Ripe E, Hornblad Y, Tegner K: Oral administration of terbutaline in asthmatic patients. Eur J Respir Dis Suppl. 1984;134:171-9.
7 Dailymed: Terbutaline Sulfate Oral Tablet
8 Fellner C: Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012 Sep;37(9):503-30.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11.
12 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
13 Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999 Mar 1;95(1-2):165-73. doi: 10.1016/s0165-5728(99)00011-9.
14 Polymorphism of the AHSG gene is associated with increased adipocyte beta2-adrenoceptor function. J Lipid Res. 2005 Oct;46(10):2278-81. doi: 10.1194/jlr.M500201-JLR200. Epub 2005 Jul 16.
15 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
16 Terbutaline inhibits corticotropin-releasing hormone (CRH) expression in human trophoblast cells. J Matern Fetal Neonatal Med. 2006 Nov;19(11):735-9. doi: 10.1080/14767050600886724.
17 L-type calcium channels regulate gastrin release from human antral G cells. Am J Physiol. 1997 Aug;273(2 Pt 1):G281-8. doi: 10.1152/ajpgi.1997.273.2.G281.
18 Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 1998 Dec 15;56(12):1561-9.
19 A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. doi: 10.1046/j.1365-2710.2003.00477.x.
20 Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J Clin Endocrinol Metab. 2000 Feb;85(2):692-6. doi: 10.1210/jcem.85.2.6379.
21 Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J Am Soc Nephrol. 2001 Nov;12(11):2288-2299. doi: 10.1681/ASN.V12112288.
22 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
23 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
24 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25 Canadian Pharmacists Association.
26 Cerner Multum, Inc. "Australian Product Information.".
27 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
28 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
29 Multum Information Services, Inc. Expert Review Panel.
30 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
31 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
33 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
34 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
35 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]